Top Markets
#1 Pleasing Gold Pleasing Gold +1,498.80%
#2 Ontology Gas Ontology Gas +118.93%
#3 PulseChain PulseChain +58.72%
#4 Ontology Ontology +36.39%
#5 BOOK OF MEME BOOK OF MEME +31.93%
#6 ConstitutionDAO ConstitutionDAO +31.37%
#7 Neiro Neiro +28.33%
#8 Collect on Fanable Collect on Fanable +27.71%
#9 Pump.fun Pump.fun +23.59%
#10 Unit Pump Unit Pump +23.59%
Coin of the day
Pleasing Gold Pleasing Gold
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Clasificación en acciones #25851
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Precio por acción
$15.31
Última sincronización: 2024-02-29
Capitalización bursátil
$45.70M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Icosavax, Inc. (ICVX)

Categoría

Healthcare
Ingresos de Icosavax, Inc. (ICVX)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Icosavax, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Icosavax, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US